SCHEMBL4562207

SCHEMBL4562207

CC1(C)OB(c2ccc3ocnc3c2)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
LPL P06858 13/20 0.41
LIPG Q9Y5X9 13/20 0.41
EGFR P00533 2/20 0.40
DYRK1A Q13627 1/20 0.40
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
CA12 O43570 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
ESR2 Q92731 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29487478 1.00 MEN1 (0.42) MEN1ALDH1A1GAAKMT2ALPL
SCHEMBL14662076 0.87 LPL (0.41) LPLLIPGEGFRDYRK1ACA1
SCHEMBL29414454 0.73 LPL (0.44) LPLLIPGEGFRCA1CA2
SCHEMBL17511970 0.73 LPL (0.44) LPLLIPGEGFRCA1CA2
SCHEMBL3534341 0.73 L3MBTL1 (0.46) MEN1GAAKMT2ALPLLIPG
Ammonia Solution, Strong SCHEMBL28476858 0.72 LPL (0.43) LPLLIPGEGFRCA1CA2
SCHEMBL25153352 0.72 LPL (0.38) LPLLIPGEGFR
SCHEMBL31620742 0.72 DYRK1A (0.35) DYRK1A
SCHEMBL24145464 0.72 EGFR (0.32) LPLLIPGEGFR
SCHEMBL16728679 0.72 EGFR (0.35) LPLLIPGEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136781-A ROR 1-targeted inhibitor and synthesis method and application thereof 北京大学 2025-06-13 CN claimed
US-12624003-B2 Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases CELGENE CORPORATION (US) 2026-05-12 US disclosed
EP-4267117-B1 CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CELGENE CORP (US) 2026-04-08 EP disclosed
US-20260060961-A1 SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS JAZZ PHARMACEUTICALS IRELAND LTD (IE) 2026-03-05 US disclosed
US-12448392-B2 Spiropiperidine derivatives CEPHALON LLC (US) 2025-10-21 US disclosed
US-20250282728-A1 NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR CEREVANCE INC (US) 2025-09-11 US disclosed
US-12404253-B2 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 ASTRAZENECA AB (SE) 2025-09-02 US disclosed
EP-4595753-A1 PHENYLPYRAZOLE COMPOUND, AND PLANT DISEASE CONTROL METHOD Sumitomo Chemical Company, Limited (JP) 2025-08-06 EP disclosed
EP-4581024-A1 SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS Jazz Pharmaceuticals Ireland Limited (IE) 2025-07-09 EP disclosed
CN-120136781-A ROR 1-targeted inhibitor and synthesis method and application thereof 北京大学 2025-06-13 CN disclosed
WO-2012148540-A1 COMBINATION OF KANASE INHIBITORS AND USES THREOF INTELLIKINE, LLC (US) 2012-11-01 WO disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-20120184526-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-07-19 US disclosed
US-20120184526-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-07-19 US disclosed
US-20120184526-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-07-19 US disclosed
WO-2012064642-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-05-18 WO disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
WO-2010038465-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF 旭化成ファーマ株式会社 (JP) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184526-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN MEN1 4339/4885ALDH1A1 4473/4885GAA 787/4885
US-20260060961-A1 SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS KRAS, NRAS, HRAS MEN1 977/4885ALDH1A1 1940/4885GAA 3396/4885
US-12404253-B2 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 CX3CR1, CCR2, CCR5 MEN1 3978/4885ALDH1A1 1531/4885GAA 3696/4885
US-12448392-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 MEN1 3012/4885ALDH1A1 128/4885GAA 946/4885
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 MEN1 2532/4885ALDH1A1 1380/4885GAA 3750/4885
US-12624003-B2 Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases S1PR5, LPAR5, S1PR2 MEN1 2509/4885ALDH1A1 1387/4885GAA 2987/4885
US-20250282728-A1 NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR GPR55, GPR68, GPR65 MEN1 1451/4885ALDH1A1 973/4885GAA 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.